Loading…
This event has ended. Visit the official site or create your own event on Sched.
View analytic

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Friday, April 27
 

8:30am

Complimentary Continental Breakfast
Friday April 27, 2018 8:30am - 9:00am
TBA

9:00am

Opening Remarks
Friday April 27, 2018 9:00am - 9:10am
TBA

9:10am

Advances in Basic and Clinical Immunology 2018
The management of IMIDs requires the integration of the latest advances in basic, translational, and clinical immunology into targeted therapeutic strategies. To guide this process, success stories from aligned fields can be used to increase our understanding of disease pathology and improve the quality of care.

For example, recent progress in the primary immunodeficiency field has clarified that many of these disorders present with autoimmune manifestations, and elucidation of the biologic underpinnings of these conditions has led to the development of targeted therapies. Noteworthy immunologic advances have also been achieved in the field of oncology, with the emergence of immunologic checkpoint inhibitors hailed as one of the most significant advances in biomedicine over the past five years.

However, these checkpoint inhibitors have also generated new clinical challenges in their potential for immunologic adverse effects, which require prompt intervention to ensure continued patient adherence and positive outcomes.

Finally, chimeric antigen receptor (CAR) T cells represent the cutting edge in oncology treatment and are poised to rapidly transform this field in the near future. Overall, the outlook for immunologic and inflammatory medicine appears bright, with movement toward individualized therapeutic strategies offering new hope for improved outcomes. 

Speakers
avatar for Leonard H. Calabrese, DO

Leonard H. Calabrese, DO

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western University; R.J. Fasenmyer Chair of Clinical Immunology, Cleveland Clinic
Leonard H. Calabrese, DO, heads Cleveland Clinic's Section of Clinical Immunology and manages its Clinical Immunology Clinic. He specializes in diseases of the immune system -- in particular, immunodeficiency diseases, such as human immunodeficiency virus (HIV) and other chronic viral... Read More →


Friday April 27, 2018 9:10am - 9:50am
TBA

9:50am

Epigenetics for the Clinician - What this Means for Managing IMIDs
The complex pathophysiology of immune-mediated inflammatory diseases (IMIDs) cannot be explained by genetic factors alone. Multiple studies have begun to implicate epigenetic mechanisms, including DNA methylation, histone modification, and noncoding RNAs, in the development and progression of these disorders through the modulation of pro-inflammatory cytokines. Environmentally-influenced changes in gene expression without alterations in the genomic sequence have been linked to a number of IMIDs, including RA, systemic lupus erythematosus (SLE), and psoriatic arthritis, through epigenome-wide association studies (EWAS). As medical technology continues to advance, epigenetic targets identified by such studies are beginning to emerge as viable treatment options.

In addition, the identification of epigenetic biomarkers that predict disease prevalence and activity has the potential to facilitate early preventative intervention, ultimately reducing the costs of care while improving patient outcomes.

In this lecture, the results of epigenetic studies will be presented in the context of their potential impact on inflammatory disease management, and the most advanced areas of epigenetic drug development will be discussed. Ultimately, a thorough understanding of the epigenetic mechanisms associated with particular inflammatory diseases is poised to transform the standard of care, providing new insights into disease development and progression for more effective treatment of these complex pathologies. 

Speakers
avatar for Joel Pekow, MD

Joel Pekow, MD

Assistant Professor of Medicine, Section of Gastroenterology, University of Chicago


Friday April 27, 2018 9:50am - 10:30am
TBA

10:30am

Recent Advances in the Treatment of Moderate-to-Severe Psoriasis: A Focus on Targeted Agents
Speakers
avatar for Joel M. Gelfand, MD, MSCE

Joel M. Gelfand, MD, MSCE

Professor, Dermatology and Epidemiology; Vice Chair, Clinical Research; Director, Psoriasis and Phototherapy Treatment Center, University of Pennsylvania Perelman School of Medicine
Joel M. Gelfand is Professor of Dermatology and of Epidemiology (tenured); Vice Chair of Clinical Research (Dermatology), Senior Scholar, Center for Clinical Epidemiology and Biostatistics; Associate Fellow, Center for Public Health Initiatives; Medical Director of the Clinical Studies... Read More →


Friday April 27, 2018 10:30am - 11:10am
TBA

11:10am

Biological Agents in Rheumatology: A Virtual Reality Tour through Psoriatic Arthritis and Rheumatoid Arthritis
The world of immune-mediated inflammatory diseases (IMIDs) is rapidly evolving with advances in understanding the underlying mechanisms and inflammatory pathways across diseases, a growing appreciation of how to maximize existing therapies, and an expanding treatment armamentarium that includes novel and targeted treatments that o er improved outcomes and safety.

Thus, this session will focus on latest IMID research and its application to clinical practice and will explore new and emerging agents, recent data that may affect the management of special populations and comorbid IMIDs, and other hot topics in autoimmune diseases. 

Friday April 27, 2018 11:10am - 12:10pm
TBA

12:10pm

LUNCH Innovation Theater - Taltz: Perspectives from Dual Specialities
Sponsored by Lilly

Speakers
ES

Evan Siegel, MD

Clinical Assistant Professor of Medicine Partner, Arthritis and Rheumatism Associates Georgetown University School of Medicine
AG

Alice Gottlieb, MD, PhD

Professor of Dermatology New York Medical College at Metropolitan Hospital


Friday April 27, 2018 12:10pm - 1:25pm
TBA

1:35pm

WORKSHOPS: Select 1 of 3 Topics
Friday April 27, 2018 1:35pm - 2:15pm
TBA

1:35pm

Updates in Neutrophilic Dermatoses
The neutrophilic dermatoses are a heterogeneous group of dermatologic disorders united by the presence of inflammatory skin lesions, in the absence of infection, that are histologically dominated by infiltrating neutrophils. The dermatologic layer of infiltration determines the classification and clinical manifestations of these conditions, which often co-present with systemic autoimmune disorders or hematologic malignancies. Significant overlap between the neutrophilic dermatoses complicates their identification and subsequent management, requiring a thorough understanding of the similarities and differences between disorders.

This lecture will discuss the clinical aspects that define the major neutrophilic dermatoses, and provide an update on the latest diagnostic criteria, treatment options, and prognoses associated with each disorder in order to facilitate the design of appropriate management plans. 

Speakers
avatar for Mital Patel, MD

Mital Patel, MD

Director, Hidradenitis Suppurativa and Neutrophilic Dermatoses Clinic; Assistant Program Director, Dermatology and Rheumatology Fellowship; Instructor in Dermatology, Harvard Medical School; Associate Physician, Department of Dermatology, Brigham and Women’s Hospital
Dr. Mital Patel is a dermatologist at Brigham and Women’s Hospital where she specializes in complex medical dermatology.  She has completed a dermatology-rheumatology fellowship and is an expert in connective tissue diseases. Her research interest is in neutrophilic based skin... Read More →


Friday April 27, 2018 1:35pm - 2:15pm
ROOM 3 - TBA

1:35pm

Dysplasia Surveillance in IBD
This session is brought to you in collaboration with Advances in Inflammatory Bowel Diseases (AIBD).

Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer, requiring regular surveillance colonoscopy for the timely identification of the dysplasia that often serves as a predictor of malignancy. The advent of newer endoscopic techniques has rendered dysplasia surveillance more effective than ever before, but created variability between available guideline recommendations and current practices.

This lecture will outline the latest consensus guidelines for dysplasia surveillance in light of these technologic advances, providing recommendations on colonoscopy and biopsy technique and subsequent approaches to management. Effective implementation of surveillance strategies is essential to ensure timely dysplasia identification and treatment that mitigates the risk of colorectal cancer in patients with IBD. 

Speakers
avatar for Francis A. Farraye, MD, MSc

Francis A. Farraye, MD, MSc

Clinical Director, Gastroenterology; Director, Inflammatory Bowel Disease Center, Boston Medical Center; Professor of Medicine, Boston University School of Medicine
Francis A. Farraye, M.D., MSc, Clinical Director, Section of Gastroenterology, Co-Director, Center for Digestive Disorders and Director of the Inflammatory Bowel Disease Center, Boston Medical Center, Professor of Medicine, Boston University School of Medicine   Dr. Farraye received... Read More →



Friday April 27, 2018 1:35pm - 2:15pm
ROOM 2 - TBA

1:35pm

The Treatment of Giant Cell Arteritis Current Era: IL-6 blockade and other treatment strategies
Speakers
avatar for Sebastian Unizony, MD

Sebastian Unizony, MD

Co-Director, Vasculitis and Glomerulonephritis Center, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School


Friday April 27, 2018 1:35pm - 2:15pm
TBA

2:15pm

WORKSHOPS: Select 1 of 3 Topics
Friday April 27, 2018 2:15pm - 2:55pm
TBA

2:15pm

Complex Connective Disease Cases
Speakers
avatar for Ruth Ann Vleugels, MD, MPH

Ruth Ann Vleugels, MD, MPH

Director, Autoimmune Skin Disease Program, Program Director, Dermatology-Rheumatology Fellowship, Vice-Chair, Brigham and Women's Hospital Department of Dermatology, Associate Professor, Harvard Medical School
Ruth Ann Vleugels, MD, MPH serves as Director of the Autoimmune Skin Disease Program at Brigham and Women’s Hospital and Co-Director of the Rheumatology-Dermatology Clinic at Boston Children’s Hospital. Her clinical research, which focuses on rare autoimmune skin diseases and... Read More →


Friday April 27, 2018 2:15pm - 2:55pm
ROOM 3 - TBA

2:15pm

Redefining "Disease Severity" in IBD
This session is brought to you in collaboration with Advances in Inflammatory Bowel Diseases (AIBD).

Despite evidence that early intervention with biologics improves response rates and patient outcomes in IBD, most clinical trials, indications for approved agents, and current treatment algorithms limit the use of these therapies to late-stage disease. This delay is due at least in part to the lack of standardized criteria for defining IBD severity, particularly as the disease progresses.

This lecture will outline the expert consensus that IBD severity is comprised of multiple factors, including the impact of the disease on the patient, its inflammatory burden, and the history/course of the disease. By redefining how the field thinks about IBD, a standardized definition of severity will facilitate the investigation and use of emerging therapeutic options in patients with early- or mid-stage disease, and promises to reduce healthcare costs and improve patient quality of life moving forward. 

Speakers
avatar for Stephen B. Hanauer, MD

Stephen B. Hanauer, MD

Clifford Joseph Barboka Professor of Medicine, Northwestern University Feinberg School of Medicine; Medical Director, Digestive Health Center
Stephen B. Hanauer, MD, FACG is an internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs.   Dr. Hanauer is a board certified... Read More →



Friday April 27, 2018 2:15pm - 2:55pm
ROOM 2 - TBA

2:15pm

Management of Rheumatologic Side Effects of Anti-PD-1 Therapy
The emergence of anti-PD-1/PD-L1 immunotherapies is poised to revolutionize the field of oncology, substantially improving patient outcomes across a number of malignancies, including melanoma, non-small cell lung cancer, and urothelial cancers. Many tumors exploit the endogenous immunologic checkpoint pathway by expressing high levels of PD- L1, enabling them to evade attack and continue growth unchecked. Inhibitors of the PD-1/PD-L1 pathway relieve this immunologic checkpoint, promoting the effective and relatively specific destruction of malignant cells.

However, it is inevitable that such immune activation will also have some impact on healthy cells, leading to the development of immune-related adverse events (irAEs), primarily dermatologic, gastrointestinal, or endocrine in nature. Rheumatologic side effects resembling autoimmune responses have also been reported, often requiring dose modification of the checkpoint inhibitor as well as immunosuppressive or additional biologic therapy.

As the use of checkpoint inhibitors becomes increasingly widespread in cancer care, it is essential that rheumatologists are prepared to work together with oncology specialists for the timely identification and treatment of these adverse effects, employing effective management strategies that facilitate continued adherence to checkpoint inhibitor therapies while mitigating the rheumatologic side effects that may result. 

Speakers
avatar for Leonard H. Calabrese, DO

Leonard H. Calabrese, DO

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western University; R.J. Fasenmyer Chair of Clinical Immunology, Cleveland Clinic
Leonard H. Calabrese, DO, heads Cleveland Clinic's Section of Clinical Immunology and manages its Clinical Immunology Clinic. He specializes in diseases of the immune system -- in particular, immunodeficiency diseases, such as human immunodeficiency virus (HIV) and other chronic viral... Read More →


Friday April 27, 2018 2:15pm - 2:55pm
ROOM 1 - TBA

2:55pm

Complimentary Refreshments
Friday April 27, 2018 2:55pm - 3:05pm
TBA

3:05pm

Keynote Presentation - Patient Perspective: Living Life with Multiple Immune-Mediated Inflammatory Diseases
This session will ground participants in the reason physicians practice medicine...the patient. Lilly Stairs, a patient advocate living life with both Crohn’s disease and Psoriatic Arthritis, willshare her journey and illuminate the burdens associated with being a chronic illness patient. Weaving together her experience along with the experiences of fellow patients from across thecountry, Stairs will uncover best practices for shared decision-making and help physicians think critically about the coordination of care and ways to support their patients living with multiple chronic illnesses. 

Speakers
avatar for Lilly Stairs

Lilly Stairs

Head of Patient Advocacy, Clara Health; Board Member, American Autoimmune Related Diseases Association (AARDA)
Lilly is a dynamic and driven young professional passionate about making a positive | impact on the lives of others. She has served in the advocacy field for 10 years, starting | in the anti-bullying sphere and transitioning into patient advocacy after she was | diagnosed with multiple... Read More →


Friday April 27, 2018 3:05pm - 3:55pm
TBA

3:55pm

Grand Opening of Exhibit Hall
Friday April 27, 2018 3:55pm - 5:25pm
TBA

5:10pm

DINNER Innovation Theater - The Role of IL-6 in Rheumatoid Arthritis
Sponsored by Sanofi/Regeneron

Speakers
avatar for Leonard H. Calabrese, DO

Leonard H. Calabrese, DO

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western University; R.J. Fasenmyer Chair of Clinical Immunology, Cleveland Clinic
Leonard H. Calabrese, DO, heads Cleveland Clinic's Section of Clinical Immunology and manages its Clinical Immunology Clinic. He specializes in diseases of the immune system -- in particular, immunodeficiency diseases, such as human immunodeficiency virus (HIV) and other chronic viral... Read More →


Friday April 27, 2018 5:10pm - 6:25pm
TBA
 
Saturday, April 28
 

7:15am

BREAKFAST Innovation Theater - Consider Stelara® As a First-Line Biologic Treatment For Adults With Moderately To Severely Active Crohns Disease
Sponsored by Janssen

Speakers
CA

Charles A. Sninsky, MD

Prior to joining Digestive Disease Associates, Dr. Sninsky was professor of medicine and chief of Gastroenterology at Shands Teaching Hospital at the University of Florida and at the Gainesville VA Medical Center. He also was previously a professor of medicine and associate chief... Read More →


Saturday April 28, 2018 7:15am - 8:30am
TBA

8:30am

Morning Welcome
Saturday April 28, 2018 8:30am - 8:35am
TBA

8:35am

Oculus Virtual Reality View: New Biologics for Improved Skin Clearance in Psoriasis
Advances in understanding psoriasis pathophysiology have led to a variety of anti-psoriatic therapies, including small molecules and biologic agents. Current and emerging biologic agents may confer improved disease management as well as the potential to reduce associated comorbidities, such as psoriatic arthritis, compared with traditional systemic treatments. Thus, the need to define treatment goals and measure treatment outcomes by means of parameters of clinical severity and quality of life has intensified.

This session will focus on the underlying immunologic interaction and signaling mechanisms in psoriatic diseases as a foundation for the latest targeted treatments, such as mechanisms underlying itch, the role of inflammation in psoriatic and cardiovascular disease, and the mechanisms by which some targeted agents provide more rapid responses and improved patient outcomes. Factors such as quality of life and self-perception that can help clinicians differentiate among available treatment options will be explored. Lastly, key learnings will be applied by integrating individual patient needs, existing comorbidities, patient preferences, and available targeted and biologic agents into individualized treatment plans. 

Speakers
avatar for Joel M. Gelfand, MD, MSCE

Joel M. Gelfand, MD, MSCE

Professor, Dermatology and Epidemiology; Vice Chair, Clinical Research; Director, Psoriasis and Phototherapy Treatment Center, University of Pennsylvania Perelman School of Medicine
Joel M. Gelfand is Professor of Dermatology and of Epidemiology (tenured); Vice Chair of Clinical Research (Dermatology), Senior Scholar, Center for Clinical Epidemiology and Biostatistics; Associate Fellow, Center for Public Health Initiatives; Medical Director of the Clinical Studies... Read More →


Saturday April 28, 2018 8:35am - 9:35am
TBA

9:35am

The Dawn of Biosimilars in the Management of IMIDs: Understanding & Integrating Biosimilar Data into Informed, Collaborative Care
Biologics are one of the primary technologic developmental areas in medical research and play a vital role in the treatment of many chronic and complex autoimmune diseases; however, they are expensive and may not be accessible to all patients. Thus, efforts are widely underway to develop biosimilars, where the unique development process allows for cost savings while offering the clinical efficacy and safety benefits of biologics.

With several biosimilars already approved and more on the horizon across a variety of IMIDs, there exists an urgent need to educate specialists on the features of biosimilars, the clinical data package and regulatory requirements, and how to best incorporate biosimilars into the IMID treatment armamentarium. 

Speakers

Saturday April 28, 2018 9:35am - 10:15am
TBA

10:15am

Overcoming Diagnostic and Treatment Challenges in Pemphigus Vulgaris
Speakers
avatar for Donna Culton, MD, PhD

Donna Culton, MD, PhD

Assistant Professor, Department of Dermatology, UNC School of Medicine


Saturday April 28, 2018 10:15am - 10:45am
TBA

10:45am

11:20am

New Advances in the Impact of Anti-Inflammatory Treatment on Cardiovascular Risk
The role of chronic inflammation in the pathology and progression of immune-mediated diseases of the skin, joints, and bowel is well-established. However, there is an emerging appreciation for the role of chronic inflammation in cardiovascular disease as a major driver of atherosclerosis and other cardiovascular events. Thus, many of the immune- targeted biologics that have begun to revolutionize the management of skin, joint, and bowel diseases may have a therapeutic role in cardiovascular disease as well.

In this lecture, learn about the areas of overlap and intersection between chronic inflammation and cardiovascular disease, and the implications of this relationship on treatment. 

Speakers
avatar for Joel M. Gelfand, MD, MSCE

Joel M. Gelfand, MD, MSCE

Professor, Dermatology and Epidemiology; Vice Chair, Clinical Research; Director, Psoriasis and Phototherapy Treatment Center, University of Pennsylvania Perelman School of Medicine
Joel M. Gelfand is Professor of Dermatology and of Epidemiology (tenured); Vice Chair of Clinical Research (Dermatology), Senior Scholar, Center for Clinical Epidemiology and Biostatistics; Associate Fellow, Center for Public Health Initiatives; Medical Director of the Clinical Studies... Read More →


Saturday April 28, 2018 11:20am - 12:00pm
TBA

12:00pm

LUNCH Innovation Theater - Non-infectious (NI) Uveitis The Importance of Prompt Recognition and Treatment
Sponsored by AbbVie

Speakers
SD

Stephen Damien Anesi, MD

Massachusetts Eye Research & Surgery Institution


Saturday April 28, 2018 12:00pm - 1:15pm
TBA

1:25pm

WORKSHOPS: Select 1 of 3 Topics
Saturday April 28, 2018 1:25pm - 2:05pm
TBA

1:25pm

Novel Insights in Atopic Dermatitis
Atopic dermatitis carries a significant public health burden in terms of morbidity, health care utilization and costs, and its prevalence in children and adults is increasing. However, traditional approaches to management, such as topical agents and nonspecific immunosuppressants, are limited by poor efficacy, frequent adverse effects, and resultant nonadherence that have rendered patient outcomes largely suboptimal.

In this lecture, learn about recent insights gained into the diverse pathophysiology that contributes to the symptoms and progression of this disease, leading to a more individualized approach to care. With the first targeted biologic for atopic dermatitis reaching the market in 2017 and multiple additional agents under clinical investigation, the field is poised for a transformation toward individualized, targeted treatment. Designing a therapeutic approach based on the underlying pathophysiology of a given patient promises to better limit disease progression and improve patient quality of life. 

Speakers
avatar for Zelma Chiesa Fuxench, MD, MSCE

Zelma Chiesa Fuxench, MD, MSCE

Assistant Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA


Saturday April 28, 2018 1:25pm - 2:05pm
ROOM 3 - TBA

1:25pm

Treat to Target - Including Endoscopic Healing
This session is brought to you in collaboration with Advances in Inflammatory Bowel Diseases (AIBD).

The management of inflammatory diseases has traditionally focused on symptom alleviation without addressing the underlying disease pathology. However, these treatment goals are evolving in light of new insights into disease pathophysiology and therapeutic advances capable of more directly tackling the biologic activity behind the disease.

It is now believed that a treat-to-target approach using objective biological measures to regularly assess disease activity will be able to substantially improve short- and long-term outcomes and mitigate disease progression.

This lecture will discuss current guideline recommendations, as well as available and emerging therapeutic options, including targeted biologics and endoscopic healing approaches, that have made such individualized treatment goals possible. 

Speakers
avatar for Marla Dubinsky, MD

Marla Dubinsky, MD

Professor of Pediatrics; Chief, Pediatric Gastroenterology; Co-Director, Hepatology, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai
Marla C. Dubinsky received a medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at Sainte-Justine Hospital, University of Montreal in Quebec, Canada. Currently, Dr. Dubinsky is Chief of Pediatric Gastroenterology, Hepatology... Read More →



Saturday April 28, 2018 1:25pm - 2:05pm
ROOM 2 - TBA

1:25pm

Vasculitis: Prospects for More Targeted Therapies

Speakers
avatar for Paul A. Monach, MD, PhD

Paul A. Monach, MD, PhD

Rheumatologist, Boston Medical Center
Dr. Monach is Chief of the Rheumatology Section in the Boston VA Healthcare System, an Associate Professor in Medicine in the Section of Rheumatology, and Director of the Vasculitis Center of the Boston University School of Medicine and Boston Medical Center.  He received his MD... Read More →


Saturday April 28, 2018 1:25pm - 2:05pm
ROOM 1 - TBA

2:05pm

WORKSHOPS: Select 1 of 3 Topics
Saturday April 28, 2018 2:05pm - 2:45pm
TBA

2:05pm

Overlap of Pyoderma Gangrenosum
Pyoderma gangrenosum is among the most severe of the neutrophilic dermatoses, characterized by painful, enlarging ulcers. The management of this disorder is complicated by the lack of defined histologic or biologic diagnostic criteria, rendering it a diagnosis of exclusion. Moreover, more than half of patients with pyoderma gangrenosum present with a comorbid systemic inflammatory disease, such as RA or IBD. While many of the therapeutic tools to treat these comorbidities are also beneficial for pyoderma gangrenosum, the optimal treatment choice may depend on which comorbidity is present.

This lecture will discuss the clinical challenges inherent in the differential diagnosis of pyoderma gangrenosum, and o er strategies to ensure that management plans take the considerable overlap between this disorder and other inflammatory diseases into account. 

Speakers
avatar for Mital Patel, MD

Mital Patel, MD

Director, Hidradenitis Suppurativa and Neutrophilic Dermatoses Clinic; Assistant Program Director, Dermatology and Rheumatology Fellowship; Instructor in Dermatology, Harvard Medical School; Associate Physician, Department of Dermatology, Brigham and Women’s Hospital
Dr. Mital Patel is a dermatologist at Brigham and Women’s Hospital where she specializes in complex medical dermatology.  She has completed a dermatology-rheumatology fellowship and is an expert in connective tissue diseases. Her research interest is in neutrophilic based skin... Read More →


Saturday April 28, 2018 2:05pm - 2:45pm
ROOM 3 - TBA

2:05pm

Diagnosis and Management of Eosinophilic Esophagitis
This session is brought to you in collaboration with Advances in Inflammatory Bowel Diseases (AIBD).

Eosinophilic esophagitis (EoE), characterized by esophageal dysfunction and eosinophilic infiltration, has increased in prevalence in recent years to become a major cause of gastrointestinal morbidity. An increased understanding of the pathophysiology behind EoE is leading to new approaches toward diagnosis and management that take differential diagnosis and treatment targets into account.

This lecture will outline the latest clinical guidelines and expert recommendations surrounding the use of EoE diagnostic tools such as biopsy, histology, and upper endoscopy, and management strategies that both alleviate symptoms and improve esophageal histology. While multiple cytokines and a Th2 inflammatory response triggered by food or environmental antigens have been implicated in the disease, previous clinical investigation of biologics for the treatment of EoE yielded few insights. Thus, the current standard of care remains dietary modification, oral topical corticosteroid use, or esophageal dilation. The potential success of biologics currently under investigation may lead to updated treatment guidelines in the future, as our understanding of EoE continues to evolve. 

Speakers
avatar for Ikuo Hirano, MD

Ikuo Hirano, MD

Professor of Medicine, Northwestern University Feinberg School of Medicine



Saturday April 28, 2018 2:05pm - 2:45pm
ROOM 2 - TBA

2:05pm

Clinical Assessment of PSO/PsA - Patient Demonstration
Approximately 30% of psoriasis (PsO) patients develop psoriatic arthritis (PsA), a chronic inflammatory disease with a broad clinical spectrum and multi-system manifestations. The management of PsA has significantly improved in recent years with the advent of targeted biologic therapies and increasing delivery of multidisciplinary care.

This lecture will review the clinical characteristics of new and emerging PsA treatments that should inform the therapeutic decision-making process. With current management strategies advocating an aggressive approach to treatment and interdisciplinary communication, patients with PsA are beginning to see fewer symptoms, reduced disease progression, and improved quality of life. 

Speakers
avatar for Joseph F. Merola, MD, MMSc, FAAD, FACR

Joseph F. Merola, MD, MMSc, FAAD, FACR

Assistant Professor, Harvard Medical School
Joseph F. Merola, MD, MMSc, is Assistant Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School in Boston, Massachusetts. Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology.  He serves... Read More →


Saturday April 28, 2018 2:05pm - 2:45pm
ROOM 1 - TBA

2:45pm

3:20pm

SLE Chronic Disease Management Pathogenesis, Assessment, Targeted Biological Therapies, Prevention, and Long-term Care
Speakers
avatar for Michelle A. Petri, MD, MPH

Michelle A. Petri, MD, MPH

Professor of Medicine; Director of Lupus Center, Johns Hopkins University School of Medicine


Saturday April 28, 2018 3:20pm - 4:00pm
TBA

4:00pm

IL-6 in Health and Disease
As a key cytokine regulator of innate and adaptive immunity, IL-6 plays complex and diverse pro- and anti-inflammatory roles, depending on the tissue in which it is expressed. The pivotal position of the IL-6 signaling pathway is exploited in many IMIDs, including RA and GSA, with elevated IL-6 levels often correlating with disease severity.

This lecture will highlight our evolving understanding of the contribution of IL-6 to the pathophysiology of IMIDs, and provide a clinical update on the targeted biologics that are beginning to emerge as a result. With multiple agents approved, seeking expanded approval, or under clinical investigation across a wide spectrum of IMIDs, inhibitors of the IL-6 pathway are poised to shape the future of IMID care. 

Speakers
avatar for Prof. Dr. Stefan Rose-John

Prof. Dr. Stefan Rose-John

Director, Department of Biochemistry; Medical Faculty, Christian-Albrechts-University Kiel


Saturday April 28, 2018 4:00pm - 4:40pm
TBA

4:40pm

Co-Chairs Complex Clinical Case Review
The management of inflammatory disease cannot be limited to a single specialty, o en featuring multi- system manifestations that require collaboration and cooperation across disciplines such as rheumatology, immunology, dermatology, and gastroenterology.

Join the co-chairs of IAS 2018 as they present clinical cases that highlight the complexity of inflammatory disease management and demonstrate the value of multidisciplinary care. These real-world examples will underline the importance of collaboration for the effcient navigation of potential complications, comorbidities, and treatment decisions that arise during the management of complex inflammatory disease. 

Speakers
avatar for Joseph F. Merola, MD, MMSc, FAAD, FACR

Joseph F. Merola, MD, MMSc, FAAD, FACR

Assistant Professor, Harvard Medical School
Joseph F. Merola, MD, MMSc, is Assistant Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School in Boston, Massachusetts. Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology.  He serves... Read More →
avatar for Adam S Cheifetz, MD

Adam S Cheifetz, MD

Associate Professor of Medicine, Harvard Medical School; Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center
Adam S. Cheifetz graduated magna cum laude from Brown University before earning his M.D. from Cornell University Medical College. Dr. Cheifetz completed his internship and residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Gastroenterology at Yale University... Read More →
avatar for Mital Patel, MD

Mital Patel, MD

Director, Hidradenitis Suppurativa and Neutrophilic Dermatoses Clinic; Assistant Program Director, Dermatology and Rheumatology Fellowship; Instructor in Dermatology, Harvard Medical School; Associate Physician, Department of Dermatology, Brigham and Women’s Hospital
Dr. Mital Patel is a dermatologist at Brigham and Women’s Hospital where she specializes in complex medical dermatology.  She has completed a dermatology-rheumatology fellowship and is an expert in connective tissue diseases. Her research interest is in neutrophilic based skin... Read More →


Saturday April 28, 2018 4:40pm - 5:20pm
TBA

5:20pm

Exhibit Hall Reception
Saturday April 28, 2018 5:20pm - 6:50pm
TBA

6:45pm

DINNER Innovation Theater - Addressing the Unique Considerations of Women with Autoimmune Diseases
Sponsored by UCB

Speakers
avatar for Leonard H. Calabrese, DO

Leonard H. Calabrese, DO

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western University; R.J. Fasenmyer Chair of Clinical Immunology, Cleveland Clinic
Leonard H. Calabrese, DO, heads Cleveland Clinic's Section of Clinical Immunology and manages its Clinical Immunology Clinic. He specializes in diseases of the immune system -- in particular, immunodeficiency diseases, such as human immunodeficiency virus (HIV) and other chronic viral... Read More →
avatar for Anita Afzali MD, MPH, FACG

Anita Afzali MD, MPH, FACG

Assistant Professor, Department of Internal Medicine Medical Director, OSU Inflammatory Bowel Disease Center Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease Division of Gastroenterology, Hepatology and Nutrition The Ohio State University Wexner Medical Center
Dr. Anita Afzali is an Assistant Professor of Clinical Medicine and a Gastroenterologist specializing in Inflammatory Bowel Disease (IBD).  She practices at The Ohio State University Wexner Medical Center.  She is the Medical Director of the OSU Inflammatory Bowel Disease Center... Read More →


Saturday April 28, 2018 6:45pm - 9:00pm
The Social Register 401 D St, Boston, MA 02210
 
Sunday, April 29
 

8:00am

BREAKFAST Innovation Theater - Giant Cell Arteritis (GCA): Disease State Overview and Current Treatment Considerations
Sponsored by Genentech

Speakers
avatar for Leonard H. Calabrese, DO

Leonard H. Calabrese, DO

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western University; R.J. Fasenmyer Chair of Clinical Immunology, Cleveland Clinic
Leonard H. Calabrese, DO, heads Cleveland Clinic's Section of Clinical Immunology and manages its Clinical Immunology Clinic. He specializes in diseases of the immune system -- in particular, immunodeficiency diseases, such as human immunodeficiency virus (HIV) and other chronic viral... Read More →


Sunday April 29, 2018 8:00am - 9:15am
TBA

9:15am

Morning Welcome
Sunday April 29, 2018 9:15am - 9:20am
TBA

9:20am

Therapeutic Drug Monitoring of Anti-TNF
Multiple patient-specific factors influence the efficacy of drugs used to treat IMIDs, and the emerging anti-TNF agents are no exception. Such properties as the levels of systemic inflammation and the development of drug-targeted antibodies influence the pharmacokinetics and pharmacodynamics of these drugs, resulting in patient-to-patient differences in effective dosing and exposure that can change over time. The proactive use of therapeutic drug monitoring (TDM) is increasingly recognized as a way to maintain response to therapy for the duration of treatment.

This lecture will highlight the benefits of TDM and discuss TDM implementation strategies as part of a treat-to-target, personalized approach to the management of IMIDs. 
 

Speakers
avatar for Adam S Cheifetz, MD

Adam S Cheifetz, MD

Associate Professor of Medicine, Harvard Medical School; Director, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center
Adam S. Cheifetz graduated magna cum laude from Brown University before earning his M.D. from Cornell University Medical College. Dr. Cheifetz completed his internship and residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Gastroenterology at Yale University... Read More →


Sunday April 29, 2018 9:20am - 10:00am
TBA

10:00am

Psoriatic Arthritis: New Choices and Treatment Options
While the treatment armamentaria for PsO and PsA have improved significantly, appropriate diagnosis and assessment are required for these innovations to translate to improved outcomes. The early detection of PsO and PsA enables the timely initiation of treatment to prevent disease progression, while subsequent assessment of the clinical response to treatment allows issues of dose adjustment, medication switching, and adherence to be promptly addressed.

This patient demonstration will illustrate the use of validated assessment tools for PsO and PsA in practice and confirm assessment as a critical component of any successful management plan for these disorders. 

Speakers
avatar for Joseph F. Merola, MD, MMSc, FAAD, FACR

Joseph F. Merola, MD, MMSc, FAAD, FACR

Assistant Professor, Harvard Medical School
Joseph F. Merola, MD, MMSc, is Assistant Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School in Boston, Massachusetts. Dr. Merola is board-certified in Dermatology, Internal Medicine, and Rheumatology.  He serves... Read More →


Sunday April 29, 2018 10:00am - 10:40am
TBA

10:40am

Predicting and Preventing Serious lnfections with Biologic Therapies
Speakers
avatar for Kevin Winthrop, MD, MPH

Kevin Winthrop, MD, MPH

Associate Professor, OHSU-PSU School of Public Health


Sunday April 29, 2018 10:40am - 11:20am
TBA

11:20am

Managing IBD with Targeted Pathophysiologic Strategies
Advances in the understanding of inflammatory cascades and the role of cytokines and cell adhesion molecules in IBD pathogenesis has led to a therapeutic shi from general immunosuppressive therapy toward a more pathway-based approach. The identification of specific immunomodulatory molecules that possess defined pathogenic roles, such as pro-inflammatory cytokines, led to the advent of several anti-TNF monoclonal antibodies that have become the mainstay of IBD treatment.

However, the utilization of these agents is o en not maximized. Even among patients appropriately treated with anti-TNF agents, less than half achieve clinical remission and mucosal healing, suggesting the involvement of other immunologic pathways.

Thus, this session will focus on maximizing current biologic therapies, overcoming treatment challenges, the underlying mechanisms of IBD as treatment targets, and exploring new and emerging therapies that may complement the current treatment armamentarium. 

Speakers
avatar for Stephen B. Hanauer, MD

Stephen B. Hanauer, MD

Clifford Joseph Barboka Professor of Medicine, Northwestern University Feinberg School of Medicine; Medical Director, Digestive Health Center
Stephen B. Hanauer, MD, FACG is an internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs.   Dr. Hanauer is a board certified... Read More →


Sunday April 29, 2018 11:20am - 12:00pm
TBA

12:05pm

LUNCH Innovation Theater - Cytokine Signaling & the JAK-STAT Pathway: Role in Rheumatoid Arthritis (RA)
Sponsored by Lilly

The JAK (Janus kinase) family members serve essential roles as the intracellular signaling effectors of cytokine receptors. This family, comprising JAK1, JAK2, JAK3, and TYK2 (nonreceptor tyrosine-protein kinase 2), was first described nearly 30 years ago, but the complexities underlying their activation, regulation and pleiotropic signaling functions are still being explored.

At the molecular level, recent studies have greatly advanced our knowledge of the structures and organization of the component pseudokinase and kinase domains within the JAKs, the pathway of JAK activation and, in particular, the role of the pseudokinase domain as a suppressor of the adjacent tyrosine kinase domain’s catalytic activity.

Here, we will review the current knowledge of the physiological functions of Janus kinase and how they may relate to inflammation in Rheumatoid Arthritis. Additionally, we will review highlights of the diversity of regulatory mechanisms utilized by the JAK family to maintain signaling fidelity, and explore possible capabilities of ATP competitive kinase inhibitors.

Speakers
avatar for Theresa Lawrence Ford, MD

Theresa Lawrence Ford, MD

Medical Director & CEO, North Georgia Rheumatology Group
Theresa Lawrence Ford is Medical Director and CEO of North Georgia Rheumatology Group and an active staff member at Gwinnett Medical Center Hospitals in Lawrenceville, Georgia. She also practices in a single-specialty group in Gwinnett County, Georgia. Dr. Lawrence Ford received her... Read More →


Sunday April 29, 2018 12:05pm - 1:20pm
TBA

1:25pm

Exploring the Role of JAK-Inhibitors Across the Spectrum of IMIDs
Speakers
avatar for Vibeke Strand, MD, MACR, FACP

Vibeke Strand, MD, MACR, FACP

Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University


Sunday April 29, 2018 1:25pm - 2:05pm
TBA

2:05pm

Managing Pregnancy and IMIDs
The management of IMIDs during pregnancy is particularly challenging, requiring a balance between maintaining disease control and adapting drug therapy to ensure the safety of the developing fetus. Moreover, pregnancy results in immunologic changes that can alleviate or worsen IMID symptoms, often requiring a different approach to management than what was successful pre-conception.

In this lecture, learn about the unique considerations for managing the pregnant patient with IMID, including medication withdrawal and switching, patient counseling strategies, and the safety data and indications surrounding available therapeutic options, to ensure the health and well-being of both mother and child throughout the pregnancy and post-partum periods. 

Speakers
avatar for Marla Dubinsky, MD

Marla Dubinsky, MD

Professor of Pediatrics; Chief, Pediatric Gastroenterology; Co-Director, Hepatology, Susan and Leonard Feinstein IBD Center, Icahn School of Medicine, Mount Sinai
Marla C. Dubinsky received a medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at Sainte-Justine Hospital, University of Montreal in Quebec, Canada. Currently, Dr. Dubinsky is Chief of Pediatric Gastroenterology, Hepatology... Read More →


Sunday April 29, 2018 2:05pm - 2:45pm
TBA

2:45pm

Fecal Microbiota Transplantation and its Emerging Role in Immune Mediated Inflammatory Diseases
It is now understood that the intestinal microbiome exerts a profound effect on the development of IMIDs, such as inflammatory bowel disease, Crohn’s disease, and ulcerative colitis, with abnormal bacterial composition or function present in many of these conditions.

Traditional approaches toward manipulating intestinal microbiota, including antibiotics and probiotics, have met with only limited success. Fecal microbiota transplantation (FMT) has emerged as an alternative mechanism through which to restore intestinal microbial homeostasis for the treatment of IMIDs, with multiple studies showing encouraging rates of response and remission.

This lecture will outline the results surrounding the use of FMT in IMID treatment to date, as well as discuss current and future approaches and challenges in this evolving therapeutic field. 

Speakers
avatar for Jessica R. Allegretti, MD, MPH

Jessica R. Allegretti, MD, MPH

Director, Fecal Microbiota Transplant Program; Attending Gastroenterologist, Brigham and Women's Hospital; Instructor of Medicine, Harvard Medical School
Dr. Jessica Allegretti is an attending gastroenterologist at the Brigham and Women’s Hospital Crohn’s and Colitis Center, where she serves as the center’s Director of Clinical Trials as well as the hospital’s Fecal Transplant Program Director. Dr. Allegretti’s research focuses... Read More →


Sunday April 29, 2018 2:45pm - 3:25pm
TBA

3:25pm

Closing Remarks
Sunday April 29, 2018 3:25pm - 3:30pm
TBA

3:30pm

4:00pm

5:00pm